![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Pevarello Paolo Villa Manuela
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.15, Iss.6, 2005-06, pp. : 675-703
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cyclin-dependent kinase inhibitors closer to market launch?
By Galons Hervé
Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets, Vol. 11, Iss. 3, 2010-03 ,pp. :